safety and effectiveness of trappa ethanolamine tablets combined with ciclosporin in the treatment of primary treatment of non-severe aplastic anemia

Conditions: Non-severe Aplastic Anemia

Summary: this is a multicenter, randomized, double-blind, and open-label, placebo-controlled phase ii clinical study. in order to evaluate the effectiveness and safety of trappa ethanolamine tablets combined with ciclosporin in the treatment of patients with non-severe aplastic anemia.


Eligibility criteria:
inclusion criteria: 1. 14-75 years old (including boundary value, whichever is at the time of signing the informed consent form), gender is not limited. 2. diagnosed with non-heavy aplastic anemia within 6 months 3. life functional status (ecog) score 0-1 4. those who understand the research procedures and methods, voluntarily participate in this experiment, and sign the informed consent form in writing exclusion criteria: 1. total blood cell loss and myelohypoproliferative diseases caused by other reasons 2. chromosome karyotype analysis during screening shows clonal cytogenetic abnormalities 3. meet the severe aplastic anemia 4. paroxysmal sleep hemoglobinuria (pnh) clone ≥50% or hemolytic pnh clone 5. randomly receive atg, ciclosporin, tpo-r agonists, androgens and other drugs to treat the relapse without completing the elution 6. pre-randomized treatment with erythropoietin 7. pre-randomized use of corticosteroids, g-csf and gm-csf treatment 8. people with a history of hematopoietic stem cell transplantation 9. subjects who had deep vein thrombosis, myocardial infarction, cerebral infarction or peripheral arterial embolism in the first 12 months 10. previous history of liver cirrhosis or portal hypertension 11. when screening, alanine aminotransferase, barley transaminase, total bilirubin and blood creatinine are higher than the upper limit of normal value 12. hiv infection or carrier in the past or screening; hepatitis c antibody positive; hepatitis b surface antigen positive or hepatitis b core antibody positive, and hbv-dna test indicates virus replication 13. patients with randomized bleeding and/or infection that are still uncontrollable after standardized treatment 14. uncontrolled hypertension at screening, severe arrhythmia, level iii/iv (graded by the new york heart association) congestive heart failure 15. those who are known or suspected to be contraindicated or highly sensitive to trappa ethanolamine api or cyclosporine 16. the subjects had any malignant solid tumors of the organ system in the first 5 years of screening, regardless of whether they had been treated, metastasis or relapsed, except for local skin basal cell carcinoma; subjects with blood tumors found in the past or screening 17. pregnant or lactating women 18. male subjects of women of childbearing age or partners of women of childbearing age refuse to use acceptable contraceptive measures from the period of taking the drug to 28 days after the last time of taking the drug. 19. randomly participated in other clinical trials and took research drugs in the first 3 months. 20. the researchers believe that there is any situation that may cause the subject to be unable to complete the study or pose an obvious risk to the subject, or other factors that reduce the possibility of joining the group.